MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs
The Medicare Payment Advisory Commission (MedPAC) will hear from its staff on Jan. 17 about whether the 340B program gives participating hospitals an incentive to use more expensive drugs. MedPAC, which advises Congress on Medicare policy, will spend an hour and a half on the 340B matter on Day 2 of its Jan. 16-17 public meeting in Washington. 340B Report plans to be there and fill you in later on what happened.
Republican Reps. Greg Walden (Ore.) and Michael Burgess (Texas) asked MedPAC for a report about hospital mergers and hospital-physician practice consolidation in an August 2018 letter, when Walden chaired the House Energy & Commerce Committee and Burgess chaired its Subcommittee on Health. The House switched to Democratic control in 2019. Walden and Burgess specifically asked MedPAC the following about 340B in their letter:
MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs The Medicare Payment Advisory Commission (MedPAC) will hear from its staff on Jan. 17 about whether the 340B program gives participating hospitals an incentive to use
...
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
